POSARD MATTHEW L. sold 8.9% of their position (5.23K shares) of HALOZYME THERAPEUTICS, INC. on the open market
Open‑market sale worth $567.7K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 10/2/2026ACC: 0001159036-26-000133
Director
Since May 2019
-5.23K
Net shares
Net seller
$567.7K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
5.23K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−730.00
Price / share
$107.17
Trade value
$78.23K
% of position
1.2%
10/1/2026
58.84K→58.11K
Common Stock
Direct
Shares
−3.30K
Price / share
$108.45
Trade value
$357.90K
% of position
5.7%
10/1/2026
58.11K→54.81K
Common Stock
Direct
Shares
−1.10K
Price / share
$109.57
Trade value
$120.53K
% of position
2.0%
10/1/2026
54.81K→53.71K
Common Stock
Direct
Shares
−100.00
Price / share
$110.04
Trade value
$11K
% of position
0.2%
10/1/2026
53.71K→53.61K
Total
Net shares
−5.23K
Net value
-$567.66K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/1/2026 | S · Sale | −730.00 | $107.17 | $78.23K | 1.2% | 58.84K | 58.11K |
| Common Stock Direct | 10/1/2026 | S · Sale | −3.30K | $108.45 | $357.90K | 5.7% | 58.11K | 54.81K |
| Common Stock Direct | 10/1/2026 | S · Sale | −1.10K | $109.57 | $120.53K | 2.0% | 54.81K | 53.71K |
| Common Stock Direct | 10/1/2026 | S · Sale | −100.00 | $110.04 | $11K | 0.2% | 53.71K | 53.61K |
| Total | −5.23K | -$567.66K | ||||||
Derivative Transactions0
No derivative transactions reported